Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals

Author(s): Y. Y. Sun and Y. Chen

Volume 15, Issue 9, 2009

Page: [983 - 987] Pages: 5

DOI: 10.2174/138161209787582048

Price: $65

Abstract

Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. 18F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.

Keywords: 18F-FDG, positron emission tomography, SPECT, imaging, radiopharmaceutical, 9mTc, 188Re

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy